Coronary Artery Bypass, Off-PumpPCSMICSNCT04267835
Prospective Cohort Study on Minimal Invasive Coronary Surgery
An observational study of Coronary Artery Bypass, Off-Pump, run by Peking University Third Hospital at 1 site in China.
Trial summary
CABG technology is recognized as the preferred treatment, and its major adverse cardiac and cerebral event(MACCE) incidence and mortality are lower than percutaneous coronary intervention(PCI). However, the traditional CABG procedure requires sternal incision, large trauma and long recovery period after surgery. Read more about this study
- Who is it for?
- Ages 25 to 85 years
- Conditions the study is for
- Coronary Artery Bypass, Off-Pump
- What is being tested?
- MIDCAB and thoracotomy OPCABG
- Type of treatment
- Surgery or procedure
- How many people
- 400 participants
- Where
- 1 siteChina
- Study dates
- 4 Apr 2020to 31 Dec 2025
- Phase
- Observational
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 25 to 85 years
- All sexes
- No healthy volunteers
- Adult, Older adult
Study population: Patients are planned for undergoing off-pump coronary artery bypass surgery.
Who may be able to join
- Patients are planned for undergoing off-pump coronary artery bypass surgery.
Who cannot join
- BMI greater than 28
- trauma, surgical or radiotherapy history of left chest
- EF less than 40%
- Simultaneous other cardiac surgery or planned cardiopulmonary bypass
- Preoperative critical situation: acute myocardial infarction, heart failure and other conditions require emergency surgery. Preoperative nitrate drugs are difficult to control angina and needs IABP implantation.
- Respiratory function: severe hypoxemia (pO2 less than 60 mmHg without Oxygen inhalation), carbon dioxide retention (pCO2 > 50 mmHg), severe chronic obstructive pulmonary disease (FEV1/forced vital capacity less than 70% and FEV1 less than 50%)
Show all 10Show fewer
- Aortic lesions: patients with ascending aorta calcification confirmed by preoperative CT
- Peripheral vascular lesions:By the preoperative assessment with ultrasound or CT,LIMA and left subclavian artery stenosis>70% ,or bilateral femoral artery calcification, stenosis>50%
- Drug therapy: Preoperative antiplatelet or anticoagulant therapy (except aspirin and clopidogrel)
- Others: Exclusion criteria and contraindications of CABG
Trial locations and contacts
1 site in 1 country.
China1 site, 1 recruiting
- Recruiting
Peking University Third Hospital
Beijing, Beijing Municipality, 100191
Yichen Gong, Doctor, 8618611693463, 18611693463@126.com
Yunpeng Ling, Doctor, 8613910315963, yunpengling@163.com
About this study
Official title: Prospective Cohort Study on Mid-term Safety and Effectiveness of Minimal Invasive Coronary Artery Bypass Grafting
CABG technology is recognized as the preferred treatment, and its major adverse cardiac and cerebral event(MACCE) incidence and mortality are lower than percutaneous coronary intervention(PCI). However, the traditional CABG procedure requires sternal incision, large trauma and long recovery period after surgery.
How to reduce trauma and treat multiple complex coronary lesions under minimally invasive conditions has become a hot spot. MIDCAB surgery can complete the coronary anastomosis only by a 6-8 cm incision in the left chest. It has been more than ten years since the first literature report in the world, however, due to the technical bottleneck, a unified and standardized surgical procedure has not yet been formed. Some centers are still in the exploratory stage, and internationally Large-scale studies of clinical outcomes (mostly less than 150 cases) have not been reported. Assessing the minimally invasive procedure's safety and effectiveness has become an urgent problem to be solved.
Read more
At present, our center has completed nearly 200 cases of small incision multi-coronary coronary artery bypass graft surgery. The investigators evaluate the patency of the graft by the postoperative of angiography, the patency of grafts is more than 95%, and there is no statistical difference with conventional OPCABG. On the other hand, focus on the postoperative complications, there was no significant difference in the incidence of MACCE and revascularization between the MIDCAB group and conventional surgery during hospitalization. The investigators assume that the early results of this procedure are safe and effective. MIDCAB has a congenital advantage because of its' reduction of the trauma of the thoracotomy and the aesthetics of the incision. Therefore, if a larger sample size study and mid-term follow-up results are obtained, and the conclusion prove that the safety of the small incision surgery and the patency of the grafts are not inferior to conventional surgery. The investigators can consider that minimal invasive coronary surgery(MICS) is a technique worth trying to promote.
Through this prospective cohort study, the investigators evaluated the safety of MICS through mid-term follow-up results and asses the efficiency by the results of grafts patency (angiography or CT within 30 days after surgery) and medical outcomes study-short from scores(SF-36), establish the surgical standard and perioperative management method.
Read the detailed description
- MIDCAB procedure introduction
- Surgery preparation: General anesthesia, double lumen tracheal intubation. In the supine position, tilt 15° to the right. An automatic defibrillation electrode is attached to the right front and left rear chest wall, and the external defibrillator is connected. A small incision of 8-10 cm into the left anterior lateral 5th intercostal space was performed into the chest.
- Internal mammary artery acquisition: After entering the chest, the IMA is exposed through a new minimal invasive retraction system. Single or bilateral IMA is obtained as needed. Separate the IMA From the middle segment (non-fat muscle coverage area) applied with an electric scalpel (15J), and the free range was up to the first rib to the fifth or sixth intercostal(IMA bifurcation).
- Bypass strategy: All procedures were performed under a non-cardiopulmonary situation, and vascular anastomosis was performed with the aid of a laparoscopic cardiac stabilizer. The stabilizer is smaller and does not occupy the operating space. The head of stabilizer can be rotated 360 degrees and the target vessel can be fixed at any angle. Bilateral internal mammary artery, radial artery and saphenous vein can be used as graft vessels. The bypass strategy is not particularly different from conventional bypass surgery, including aorta(AO)-saphenous vein graft (SVG) or radial artery(RA)-X1-X2-...( sequential anastomosis), left internal mammary artery(LIMA)-right internal mammary artery(RIMA) -RA or SVG(Y)-X, RIMA-left anterior descending(LAD), LIMA-RA or RIMA or SVG(I)-X1-X2 and so on.
- Vascular anastomosis: The target vessel is exposed through the pericardial suture, the heart is locally fixed with the aid of a cardiac stabilizer, and the target vessel is inserted shunt to avoid hemodynamic disorder and arrhythmia. Vascular anastomosis is performed by 8-0 polypropylene suture.
- Aortic exposure and proximal anastomosis: Place gauze behind the aorta, expose the aorta with the right pericardial suspension suture, temporary block aortic anterior wall with a soft-chain sidewall clamp, Punch on the aortic anterior wall with 3.5mm puncher, anastomose SVG or RA on AO with 6-0 polypropylene suture.
- postoperative management: Patients go to the cardiac ICU ward postoperatively. The investigators closely observe the electrocardiogram and myocardial enzyme changes, maintain a mean arterial pressure more than 70 mmHg perfusion pressure, and the use of nitrate ester drug to relax coronary, Begin with oral aspirin (100 mg, qd) antiplatelet therapy as soon as tracheal intubation is removed. Complete chest X-ray, cardiac ultrasound and coronary angiography before discharge.
- Patient selection Because MIDCAB requires the heart to be exposed through the lateral incision, it is necessary to avoid the difficulty of exposure caused by thoracic deformity, adhesion or obesity; it is not suitable for MIDCAB in patients with extremely low cardiac function and severe heart enlargement; Because of the necessity of single-side ventilation, such as patients with severe pulmonary dysfunction before surgery, should also avoid small incision surgery. See the eligible and exclusion criteria for details.
- Baseline matching problem MIDCAB is more rigorous in terms of patient selection, such as weight, EF%, and lung function, thus the study will use a propensity score method to match the baseline of two groups to eliminate the baseline bias. Baseline factor: General: gender, age, BMI History and comorbidities:Smoke, Diabetes (diagnostic criteria: oral hypoglycemic agents, insulin therapy, HbA1c greater than 7.0%, postprandial blood glucose greater than 11.1mmol/L, fasting plasma glucose greater than 7.0mmol/L), previous stroke(CT showed large area softening lesion) and presence of neurological dysfunction (paralysis, weak muscles, aphasia, paresthesia, and difficulty urinating), Hyperlipidemia (administered or admitted to hospital serum cholesterol greater than 5.17mmol / L or 200mg / dl), high blood pressure (blood pressure greater than 140 / 90 mmHg without medication), renal insufficiency (dialysis or serum creatinine level greater than 140mmol / L ), Peripheral vascular disease (preoperative ultrasound or CT confirmed peripheral vascular stenosis greater than 50%), previous history of cardiac surgery, previous PCI history (balloon dilatation or stent implantation) Preoperative status: Classification of angina (stable angina pectoris, unstable angina pectoris, non st-t segment elevation myocardial infarction, st-t segment elevation myocardial infarction), previous myocardial infarction history(pathological Q wave on ECG, abnormal segment motion on lesion area accompany with low EF% or clear and definitely evidence of elevation of creatine kinase(CK-MB) or troponin(cTnI), New York Heart Association(NYHA) heart function classification. Preoperative examination:creatinine(Cr), N-terminal pro brain natriuretic peptide(NT-proBNP), total cholesterol(TG) and low density lipoprotein(LDL) level, preoperative cardiac function (EF%, LVEDmm), SYNTAX score (evaluation by cardiologist). Preoperative medication (within 1 week): aspirin, clopidogrel
- statistical methods The primary endpoint of 12 months MACCE will be analysis by non-inferiority method. The small incision surgery has advantage of little trauma and the aesthetics of the incision. According to the results of previous studies and literature reports, the 1 year graft's patency is assumed to be 96% in the MICS group, 96% in the control group, test performance β=90%, in the single-tail test α=0.025, △=0.06, the investigators expected the sample size of each group is required to be 168, and assume drop rate is about 15%, and finally 190-200 cases are needed in each group. In the OPCABG group, considering the propensity score matching efficiency of 0.5, it may be need more cases.
The other primary endpoints of Physical Component Scale (PCS) will be analysis by superior effect test. The higher the PCS score of SF-36 scale, the better the patient's physiological health. According to previous studies and literature reports, the average PCS score of SF-36 scale on the 30th day after CABG was 43 with a standard deviation of 10. The PCS difference of SF-36 scale with the smallest clinical significance reported in literature was 2. Through previous studies, the average PCS score on the 30th day after CABG in MICS group was 50. Assuming that the lower line of 95% confidence interval of PCS score difference between MICS-CABG group and OPCABG group is greater than 2, it is considered that the PCS score of MICS-CABG group is better than OPCABG group, with inspection level α=0.025 (one side) and inspection efficiency 1-β=0.80. The sample size of OPCABG group and MICS group is calculated to be 65 cases, with an estimated miss rate of 20%, and each group needs to include at least 82 people.
Based on the above conclusions, The investigators calculated sample size is 200 cases in each group.
After establishing the database, the logistic regression model will be established,the dependent variable is surgery procedure(MICS surgery), the independent variable are baseline factor, and the receiver operating characteristic curve(ROC) will be drawn. The logistic regression model will be used to calculate the prone score(PS) of each subject. The nearest neighbor matching method will be used to select the thoracotomy OPCABG cases in a 1:1 ratio according to the priority matching method.
According to the basic principles of Intention-to-Treat (ITT), the whole analysis set was used. The analysis of the main indicators will include all randomized subjects, whether or not they will complete the test, the data will be included in the analysis.
Statistics data include baseline analysis, primary endpoints, secondary endpoints, observations, and compliance indicators. Measurement data that conformed to the normal distribution will be statistically described using mean ± standard deviation (χ ± S,using t test). Non-normally distributed measurement data will be statistically described using median and quartiles (using variance or nonparametric tests). The grade data will be tested using rank sum test. The count data will be statistically described as a percentage, and two or more independent sample rates will be compared using a chi-square test. Fisher's exact probability analysis will be used for indicators with low index positives (expected value <5). Survival-related data will be applied by proportional hazards model(COX) regression and survival curve risk.
Describe the missing value processing method: The estimation of the missing value of the main indicator is carried forward using the closest observation when selecting the full analysis set for statistical analysis,
5、 Ethics and safety Ethics: This research has been reviewed and filed by the Ethics Committee of the Third Hospital of Peking University. Informed consent will be signed before each participating patient was enrolled Safety: Through pre-research, MICS is a safe and effective new surgical procedure. At present, the investigators have completed more than 200 MICS operations. Only 2 of these patients died, and the postoperative complications and mid-term follow-up results were counted. The rate of graft patency and complications is not inferior to thoracotomy OPCABG surgery.
6、 Quality control Access system: MICS surgery is limited by the operation space. Although the multiple minimal invasive bypass surgery can be achieved routinely at present in our center, this surgery requires high skill and long learning curve. The cardiac surgery will strictly implement the surgeon's access qualification and have regular bypass surgery 300. For example, in the case of a small incision, only 50 patients with more than one bypass surgery, after a discussion within the department and approved by the core group, can perform small incision multi-bridge surgery.
Safeguard plan: For each case of small incision surgery, the patient's clinical data will be evaluate preoperative in our center by more than 3 senior surgeons. The surgical plan is strictly according to the standard of admission; Femoral arteriovenous will be routinely prepared for emergency cardiopulmonary bypass(CPB) and intraaortic balloon pumping(IABP) implantation. Transformation to thoracotomy surgery will be carried out if hemorrhage, uncontrollable hemodynamic disorder and malignant arrhythmia occured.
Termination of research criteria:
To ensure the safety of all candidates, a quality and safety management team will be established to monitor the complications and major safety indicators of the MICS group. The data were collected monthly to monitor serious complications (death, MACCE, unplanned revascularization, reoperation etc.) Our research will be terminated when any of the serious complications happen more than 5 cases .
- Conditions
- Coronary Artery Bypass, Off-Pump
- Being tested
- MIDCAB, thoracotomy OPCABG
- Keywords
- Coronary artery bypass grafting, Minimally Invasive Surgical Procedures, Off-pump CABG
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
MIDCABProcedure or surgery
Surgery: MIDCAB
thoracotomy OPCABGProcedure or surgery
Surgery: thoracotomy OPCABG
| Study group | Role | What they receive |
|---|---|---|
| MICS (Minimal invasive coronary surgery) | Patients undergoing MIDCAB surgery. Receives: Procedure: MIDCAB | |
| OPCABG (thoracotomy off-pump CABG) | Patients undergoing thoracotomy OPCABG surgery Receives: Procedure: thoracotomy OPCABG |
What is being measured
The primary outcome is the main question the study is designed to answer.
Rate of 1 years graft occlusion rate
12 months occlusion rate of graft(Evaluate by angiography of CT angiography )
Measured: 12 months after the MIDCAB or OPCABG surgery
30 days PCS scores
PCS scores calculated from the SF-36
Measured: 30days after the MIDCAB or OPCABG surgery
30 days mental health summary scales(MCS) of SF-36 scores
MCS scores calculated from the SF-36
Measured: 30days after the MIDCAB or OPCABG surgery
Secondary outcomes (5)
Rate of 30 days graft occlusion rate
perioperative occlusion rate of graft(Evaluate by angiography of CT angiography )
Measured: within 30days after the MIDCAB or OPCABG surgery
MCS scores
MCS scores calculated from the SF-36
Measured: 7 days, 3 months, 6 months and 12 months after the MIDCAB or OPCABG surgery
PCS scores
PCS scores calculated from the SF-36
Measured: 7 days, 3 months, 6 months and 12 months after the MIDCAB or OPCABG surgery
Rate of Perioperative MACCE
Major adverse cardiovascular and cerebrovascular events( Composite endpoint of Myocardial infarction, Stroke and death)
Measured: Within 30 days of the MIDCAB or OPCABG surgery
Rate of mid-term MACCE incidence
Major adverse cardiovascular and cerebrovascular events( Composite endpoint of Myocardial infarction, Stroke and death)
Measured: 12 months after the MIDCAB or OPCABG surgery
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted13 Feb 2020
- Study start4 Apr 2020
- Primary completion31 Dec 2023 (estimated)
- Study completion31 Dec 2025 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (1)Papers the sponsor has linked to this study.
- Other trials for Coronary Artery Bypass, Off-PumpStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Prospective
- Enrolment
- 400 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Peking University Third Hospital
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor
- Investigators
- Yunpeng Ling, Doctor, Study chair, Peking University Third HospitalYichen Gong, Doctor, Principal investigator, Peking University Third Hospital
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT04267835
- Sponsor's protocol ID
- PKU MICS study
- Acronym
- PCSMICS
- Status last verified
- Feb 2020
- First submitted
- 19 May 2019
- Last updated
- 9 Nov 2020
- Results posted
- No
- Data monitoring committee
- Yes
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Publications
Ding T, Gong Y, Fu Y, Cui Z, Wu S, Yang W, Yang H, Zhao H, Feng H, Zheng H, Meng L, Guo R, Han H, Ling Y. Minimally invasive coronary bypass grafting for treating multivessel coronary disease: A single-center prospective pilot study. JTCVS Open. 2025 May 4;25:96-119. doi: 10.1016/j.xjon.2025.03.030. eCollection 2025 Jun.
PubMed 40631015
Study at a glance
From the registry record, last updated by the sponsor on 9 Nov 2020. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Prospective Cohort Study on Mid-term Safety and Effectiveness of Minimal Invasive Coronary Artery Bypass Grafting
- ClinicalTrials.gov ID
- NCT04267835
- Acronym / sponsor ID
- PCSMICS / PKU MICS study
- Conditions
- Coronary Artery Bypass, Off-Pump
- Keywords
- Coronary artery bypass grafting, Minimally Invasive Surgical Procedures, Off-pump CABG
- Study type
- Observational
- Recruitment status
- Unknown status
- Enrolment
- 400 participants (estimated)
- Lead sponsor
- Peking University Third HospitalUniversity, hospital or other
- Study start
- 4 Apr 2020 (actual)
- Primary completion
- 31 Dec 2023 (estimated)
- Study completion
- 31 Dec 2025 (estimated)
- First posted
- 13 Feb 2020 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
CABG technology is recognized as the preferred treatment, and its major adverse cardiac and cerebral event(MACCE) incidence and mortality are lower than percutaneous coronary intervention(PCI). However, the traditional CABG procedure requires sternal incision, large trauma and long recovery period after surgery.
How to reduce trauma and treat multiple complex coronary lesions under minimally invasive conditions has become a hot spot. MIDCAB surgery can complete the coronary anastomosis only by a 6-8 cm incision in the left chest. It has been more than ten years since the first literature report in the world, however, due to the technical bottleneck, a unified and standardized surgical procedure has not yet been formed. Some centers are still in the exploratory stage, and internationally Large-scale studies of clinical outcomes (mostly less than 150 cases) have not been reported. Assessing the minimally invasive procedure's safety and effectiveness has become an urgent problem to be solved.
At present, our center has completed nearly 200 cases of small incision multi-coronary coronary artery bypass graft surgery. The investigators evaluate the patency of the graft by the postoperative of angiography, the patency of grafts is more than 95%, and there is no statistical difference with conventional OPCABG. On the other hand, focus on the postoperative complications, there was no significant difference in the incidence of MACCE and revascularization between the MIDCAB group and conventional surgery during hospitalization. The investigators assume that the early results of this procedure are safe and effective. MIDCAB has a congenital advantage because of its' reduction of the trauma of the thoracotomy and the aesthetics of the incision. Therefore, if a larger sample size study and mid-term follow-up results are obtained, and the conclusion prove that the safety of the small incision surgery and the patency of the grafts are not inferior to conventional surgery. The investigators can consider that minimal invasive coronary surgery(MICS) is a technique worth trying to promote.
Through this prospective cohort study, the investigators evaluated the safety of MICS through mid-term follow-up results and asses the efficiency by the results of grafts patency (angiography or CT within 30 days after surgery) and medical outcomes study-short from scores(SF-36), establish the surgical standard and perioperative management method.
Detailed description
- MIDCAB procedure introduction
- Surgery preparation: General anesthesia, double lumen tracheal intubation. In the supine position, tilt 15° to the right. An automatic defibrillation electrode is attached to the right front and left rear chest wall, and the external defibrillator is connected. A small incision of 8-10 cm into the left anterior lateral 5th intercostal space was performed into the chest.
- Internal mammary artery acquisition: After entering the chest, the IMA is exposed through a new minimal invasive retraction system. Single or bilateral IMA is obtained as needed. Separate the IMA From the middle segment (non-fat muscle coverage area) applied with an electric scalpel (15J), and the free range was up to the first rib to the fifth or sixth intercostal(IMA bifurcation).
- Bypass strategy: All procedures were performed under a non-cardiopulmonary situation, and vascular anastomosis was performed with the aid of a laparoscopic cardiac stabilizer. The stabilizer is smaller and does not occupy the operating space. The head of stabilizer can be rotated 360 degrees and the target vessel can be fixed at any angle. Bilateral internal mammary artery, radial artery and saphenous vein can be used as graft vessels. The bypass strategy is not particularly different from conventional bypass surgery, including aorta(AO)-saphenous vein graft (SVG) or radial artery(RA)-X1-X2-...( sequential anastomosis), left internal mammary artery(LIMA)-right internal mammary artery(RIMA) -RA or SVG(Y)-X, RIMA-left anterior descending(LAD), LIMA-RA or RIMA or SVG(I)-X1-X2 and so on.
- Vascular anastomosis: The target vessel is exposed through the pericardial suture, the heart is locally fixed with the aid of a cardiac stabilizer, and the target vessel is inserted shunt to avoid hemodynamic disorder and arrhythmia. Vascular anastomosis is performed by 8-0 polypropylene suture.
- Aortic exposure and proximal anastomosis: Place gauze behind the aorta, expose the aorta with the right pericardial suspension suture, temporary block aortic anterior wall with a soft-chain sidewall clamp, Punch on the aortic anterior wall with 3.5mm puncher, anastomose SVG or RA on AO with 6-0 polypropylene suture.
- postoperative management: Patients go to the cardiac ICU ward postoperatively. The investigators closely observe the electrocardiogram and myocardial enzyme changes, maintain a mean arterial pressure more than 70 mmHg perfusion pressure, and the use of nitrate ester drug to relax coronary, Begin with oral aspirin (100 mg, qd) antiplatelet therapy as soon as tracheal intubation is removed. Complete chest X-ray, cardiac ultrasound and coronary angiography before discharge.
- Patient selection Because MIDCAB requires the heart to be exposed through the lateral incision, it is necessary to avoid the difficulty of exposure caused by thoracic deformity, adhesion or obesity; it is not suitable for MIDCAB in patients with extremely low cardiac function and severe heart enlargement; Because of the necessity of single-side ventilation, such as patients with severe pulmonary dysfunction before surgery, should also avoid small incision surgery. See the eligible and exclusion criteria for details.
- Baseline matching problem MIDCAB is more rigorous in terms of patient selection, such as weight, EF%, and lung function, thus the study will use a propensity score method to match the baseline of two groups to eliminate the baseline bias. Baseline factor: General: gender, age, BMI History and comorbidities:Smoke, Diabetes (diagnostic criteria: oral hypoglycemic agents, insulin therapy, HbA1c greater than 7.0%, postprandial blood glucose greater than 11.1mmol/L, fasting plasma glucose greater than 7.0mmol/L), previous stroke(CT showed large area softening lesion) and presence of neurological dysfunction (paralysis, weak muscles, aphasia, paresthesia, and difficulty urinating), Hyperlipidemia (administered or admitted to hospital serum cholesterol greater than 5.17mmol / L or 200mg / dl), high blood pressure (blood pressure greater than 140 / 90 mmHg without medication), renal insufficiency (dialysis or serum creatinine level greater than 140mmol / L ), Peripheral vascular disease (preoperative ultrasound or CT confirmed peripheral vascular stenosis greater than 50%), previous history of cardiac surgery, previous PCI history (balloon dilatation or stent implantation) Preoperative status: Classification of angina (stable angina pectoris, unstable angina pectoris, non st-t segment elevation myocardial infarction, st-t segment elevation myocardial infarction), previous myocardial infarction history(pathological Q wave on ECG, abnormal segment motion on lesion area accompany with low EF% or clear and definitely evidence of elevation of creatine kinase(CK-MB) or troponin(cTnI), New York Heart Association(NYHA) heart function classification. Preoperative examination:creatinine(Cr), N-terminal pro brain natriuretic peptide(NT-proBNP), total cholesterol(TG) and low density lipoprotein(LDL) level, preoperative cardiac function (EF%, LVEDmm), SYNTAX score (evaluation by cardiologist). Preoperative medication (within 1 week): aspirin, clopidogrel
- statistical methods The primary endpoint of 12 months MACCE will be analysis by non-inferiority method. The small incision surgery has advantage of little trauma and the aesthetics of the incision. According to the results of previous studies and literature reports, the 1 year graft's patency is assumed to be 96% in the MICS group, 96% in the control group, test performance β=90%, in the single-tail test α=0.025, △=0.06, the investigators expected the sample size of each group is required to be 168, and assume drop rate is about 15%, and finally 190-200 cases are needed in each group. In the OPCABG group, considering the propensity score matching efficiency of 0.5, it may be need more cases.
The other primary endpoints of Physical Component Scale (PCS) will be analysis by superior effect test. The higher the PCS score of SF-36 scale, the better the patient's physiological health. According to previous studies and literature reports, the average PCS score of SF-36 scale on the 30th day after CABG was 43 with a standard deviation of 10. The PCS difference of SF-36 scale with the smallest clinical significance reported in literature was 2. Through previous studies, the average PCS score on the 30th day after CABG in MICS group was 50. Assuming that the lower line of 95% confidence interval of PCS score difference between MICS-CABG group and OPCABG group is greater than 2, it is considered that the PCS score of MICS-CABG group is better than OPCABG group, with inspection level α=0.025 (one side) and inspection efficiency 1-β=0.80. The sample size of OPCABG group and MICS group is calculated to be 65 cases, with an estimated miss rate of 20%, and each group needs to include at least 82 people.
Based on the above conclusions, The investigators calculated sample size is 200 cases in each group.
After establishing the database, the logistic regression model will be established,the dependent variable is surgery procedure(MICS surgery), the independent variable are baseline factor, and the receiver operating characteristic curve(ROC) will be drawn. The logistic regression model will be used to calculate the prone score(PS) of each subject. The nearest neighbor matching method will be used to select the thoracotomy OPCABG cases in a 1:1 ratio according to the priority matching method.
According to the basic principles of Intention-to-Treat (ITT), the whole analysis set was used. The analysis of the main indicators will include all randomized subjects, whether or not they will complete the test, the data will be included in the analysis.
Statistics data include baseline analysis, primary endpoints, secondary endpoints, observations, and compliance indicators. Measurement data that conformed to the normal distribution will be statistically described using mean ± standard deviation (χ ± S,using t test). Non-normally distributed measurement data will be statistically described using median and quartiles (using variance or nonparametric tests). The grade data will be tested using rank sum test. The count data will be statistically described as a percentage, and two or more independent sample rates will be compared using a chi-square test. Fisher's exact probability analysis will be used for indicators with low index positives (expected value <5). Survival-related data will be applied by proportional hazards model(COX) regression and survival curve risk.
Describe the missing value processing method: The estimation of the missing value of the main indicator is carried forward using the closest observation when selecting the full analysis set for statistical analysis,
5、 Ethics and safety Ethics: This research has been reviewed and filed by the Ethics Committee of the Third Hospital of Peking University. Informed consent will be signed before each participating patient was enrolled Safety: Through pre-research, MICS is a safe and effective new surgical procedure. At present, the investigators have completed more than 200 MICS operations. Only 2 of these patients died, and the postoperative complications and mid-term follow-up results were counted. The rate of graft patency and complications is not inferior to thoracotomy OPCABG surgery.
6、 Quality control Access system: MICS surgery is limited by the operation space. Although the multiple minimal invasive bypass surgery can be achieved routinely at present in our center, this surgery requires high skill and long learning curve. The cardiac surgery will strictly implement the surgeon's access qualification and have regular bypass surgery 300. For example, in the case of a small incision, only 50 patients with more than one bypass surgery, after a discussion within the department and approved by the core group, can perform small incision multi-bridge surgery.
Safeguard plan: For each case of small incision surgery, the patient's clinical data will be evaluate preoperative in our center by more than 3 senior surgeons. The surgical plan is strictly according to the standard of admission; Femoral arteriovenous will be routinely prepared for emergency cardiopulmonary bypass(CPB) and intraaortic balloon pumping(IABP) implantation. Transformation to thoracotomy surgery will be carried out if hemorrhage, uncontrollable hemodynamic disorder and malignant arrhythmia occured.
Termination of research criteria:
To ensure the safety of all candidates, a quality and safety management team will be established to monitor the complications and major safety indicators of the MICS group. The data were collected monthly to monitor serious complications (death, MACCE, unplanned revascularization, reoperation etc.) Our research will be terminated when any of the serious complications happen more than 5 cases .
Study design
- Observational model
- Cohort
- Time perspective
- Prospective
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| MICS (Minimal invasive coronary surgery) | – | Procedure: MIDCABPatients undergoing MIDCAB surgery. |
| OPCABG (thoracotomy off-pump CABG) | – | Procedure: thoracotomy OPCABGPatients undergoing thoracotomy OPCABG surgery |
Who may qualify
- Ages
- 25 to 85 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
- Study population
- Patients are planned for undergoing off-pump coronary artery bypass surgery.
Key inclusion criteria (1 listed)
- Patients are planned for undergoing off-pump coronary artery bypass surgery.
Key exclusion criteria (10 listed)
- BMI greater than 28
- trauma, surgical or radiotherapy history of left chest
- EF less than 40%
- Simultaneous other cardiac surgery or planned cardiopulmonary bypass
- Preoperative critical situation: acute myocardial infarction, heart failure and other conditions require emergency surgery. Preoperative nitrate drugs are difficult to control angina and needs IABP implantation.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| MIDCABSurgery: MIDCAB | Procedure or surgery | MICS (Minimal invasive coronary surgery) |
| thoracotomy OPCABGSurgery: thoracotomy OPCABG | Procedure or surgery | OPCABG (thoracotomy off-pump CABG) |
Primary outcome
Rate of 1 years graft occlusion rate
Time frame: 12 months after the MIDCAB or OPCABG surgery
12 months occlusion rate of graft(Evaluate by angiography of CT angiography )
30 days PCS scores
Time frame: 30days after the MIDCAB or OPCABG surgery
PCS scores calculated from the SF-36
30 days mental health summary scales(MCS) of SF-36 scores
Time frame: 30days after the MIDCAB or OPCABG surgery
MCS scores calculated from the SF-36
5 secondary outcomes
Rate of 30 days graft occlusion rate
Time frame: within 30days after the MIDCAB or OPCABG surgery
MCS scores
Time frame: 7 days, 3 months, 6 months and 12 months after the MIDCAB or OPCABG surgery
PCS scores
Time frame: 7 days, 3 months, 6 months and 12 months after the MIDCAB or OPCABG surgery
Rate of Perioperative MACCE
Time frame: Within 30 days of the MIDCAB or OPCABG surgery
Rate of mid-term MACCE incidence
Time frame: 12 months after the MIDCAB or OPCABG surgery
Results and safety
Results are not available in the source record.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 9 Nov 2020.
- Derived from this study: PubMed 40631015Ding T, Gong Y, Fu Y, Cui Z, Wu S, Yang W, Yang H, Zhao H, Feng H, Zheng H, Meng L, Guo R, Han H, Ling Y. Minimally invasive coronary bypass grafting for treating multivessel coronary disease: A single-center prospective pilot study. JTCVS Open. 2025 May 4;25:96-119. doi: 10.1016/j.xjon.2025.03.030. eCollection 2025 Jun.
- Individual participant dataSharing planned: No
Related trials for Coronary Artery Bypass, Off-Pump
RecruitingObservational study
Getinge's Beating Heart Product Family Post-Market Clinical Follow-up (PMCF) Study
Off Pump Coronary Artery Bypass Surgery
Recruiting
Efficacy of Multiple Nerve Blocks on the Recovery of Patients Undergoing Off Pump CABG Surgeries
Ischemic Heart Disease (IHD), Off-pump Coronary Artery Bypass
Recruiting
Multivessel Minimally Invasive Coronary Bypass Grafting as HYBRID Revascularization Versus Conventional Off-pump Coronary Artery Bypass Grafting
Coronary Artery Disease (CAD), Bypass, Cardiopulmonary
Not yet recruitingObservational study
Erector Spinae Oxygen Saturation and AKI After OPCAB
Acute Kidney Injury, Coronary Artery Disease
Recruiting
Postural Mobilization Compared to Noradrenaline Only in Off-Pump CABG Surgery
Coronary Artery Disease With Need for Bypass Surgery, Coronary Artery Disease(CAD)
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Yunpeng Ling, Doctor study chair
Peking University Third Hospital
Yichen Gong, Doctor principal investigator
Peking University Third Hospital
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Coronary Artery Bypass, Off-Pump, run by Peking University Third Hospital at 1 site in China.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 1 inclusion and 10 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: status not confirmed, as of the sponsor's last update on 9 Nov 2020. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in China. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
Results are not available in the source record.
How can a doctor refer a patient or contact the research team?
Contact Yichen Gong, Doctor (8618611693463, 18611693463@126.com), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Rate of 1 years graft occlusion rate (time frame: 12 months after the MIDCAB or OPCABG surgery). The study lists 3 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT04267835, which also lists 1 linked publication.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 9 Nov 2020; AzTrials last refreshed its copy on 1 Nov 2026.